<p>Lucid Diagnostics（纳斯达克股票代码：LUCD - 获取免费报告）在周六向投资者发布的报告中，被华尔街 Zen 的股票研究员将评级从 “持有” 下调至 “卖出”。</p>
<p>获取 <strong>Lucid Diagnostics</strong> 的提醒：</p>
<ul>
<li>十月四只最佳便士股票：高风险，高回报的选择</li>
</ul>
<p>LUCD 曾受到其他几份报告的关注。Ascendiant Capital Markets 将 Lucid Diagnostics 的目标价格从 8.25 美元上调至 9.00 美元，并在 4 月 9 日的研究报告中给予该股票 “买入” 评级。Needham &amp; Company LLC 在 3 月 26 日的报告中重申了 “买入” 评级，并对 Lucid Diagnostics 的股票设定了 3.00 美元的目标价。Weiss Ratings 在周三的报告中重申了 Lucid Diagnostics 的 “卖出（d-）” 评级。最后，BTIG Research 在 3 月 30 日的报告中重申了 “买入” 评级，并对 Lucid Diagnostics 的股票设定了 2.50 美元的目标价。四位股票研究分析师给予该股票 “买入” 评级，一位分析师给予该股票 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 4.13 美元。</p>
<p><strong>获取我们关于 Lucid Diagnostics 的最新股票报告</strong></p>
<h2>Lucid Diagnostics 价格表现</h2>
<p>Lucid Diagnostics 的股票在周五开盘价为 1.03 美元。Lucid Diagnostics 的 1 年最低价为 0.95 美元，1 年最高价为 1.70 美元。该公司的市值为 2.0111 亿美元，市盈率为-1.07，贝塔值为 1.10。该业务的 50 日移动平均价格为 1.25 美元，200 日移动平均价格为 1.19 美元。</p>
<p>Lucid Diagnostics（纳斯达克股票代码：LUCD - 获取免费报告）最近在 3 月 25 日发布了季度财报。该公司报告每股收益（EPS）为（0.10）美元，低于共识预期的（0.07）美元，差额为（0.03）美元。该公司在本季度的收入为 150 万美元，而分析师预期为 139 万美元。整体而言，研究分析师预计 Lucid Diagnostics 在当前财政年度将发布-0.22 的每股收益。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者最近买入和卖出了该公司的股票。Centiva Capital LP 在第三季度以 25,000 美元的估值收购了 Lucid Diagnostics 的新头寸。Sprott Inc.在第三季度收购了 Lucid Diagnostics 的股份，价值 25,000 美元。Cubist Systematic Strategies LLC 在第一季度以 39,000 美元的价值收购了 Lucid Diagnostics 的新股份。SG Americas Securities LLC 在第三季度以 26,000 美元的价值收购了 Lucid Diagnostics 的新股份。最后，Abel Hall LLC 在第四季度以 33,000 美元的价值收购了 Lucid Diagnostics 的新股份。目前 74.01% 的股票由机构投资者和对冲基金持有。</p>
<h2>Lucid Diagnostics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Lucid Diagnostics 是一家分子诊断公司，专注于改善口腔和咽喉癌的早期检测。该公司的旗舰产品 LucidDx 口腔细胞学刷检测试剂，结合了一种微创的刷子活检工具和专有的实验室分析，以识别指示恶性肿瘤的细胞异常。在牙科和医疗办公室收集的样本被送往 Lucid 的 CLIA 认证和 CAP 认可的实验室，在那里，先进的成像和细胞病理工作流程生成诊断报告供临床医生和患者使用。</p>
<p>自开始商业运营以来，Lucid Diagnostics 一直致力于将其检测平台整合到美国的牙科诊所、口腔外科诊所和耳鼻喉科专家中。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Lucid Diagnostics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFVDRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFVDRA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Lucid Diagnostics 吗？</h2>
<p>在你考虑 Lucid Diagnostics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Lucid Diagnostics 并不在名单上。</p>
<p>虽然 Lucid Diagnostics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LUCD

<p>华尔街禅将 Lucid Diagnostics（NASDAQ:LUCD）的评级从 “持有” 下调至 “卖出”。尽管如此，其他分析师的评级各不相同，Ascendiant Capital Markets 将其目标价上调至 9.00 美元，并维持 “买入” 评级。目前，该股票的共识评级为 “适度买入”，目标价为 4.13 美元。Lucid Diagnostics 报告季度每股亏损为（0.10 美元），未能达到预期，市值为 2.0111 亿美元。该公司专注于通过 LucidDx 口腔细胞学刷检测试剂盒进行口腔癌的早期检测</p>

<p>Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a note issued to investors on Saturday.</p>
<div class="lb-trans"><p>Lucid Diagnostics（纳斯达克股票代码：LUCD - 获取免费报告）在周六向投资者发布的报告中，被华尔街 Zen 的股票研究员将评级从 “持有” 下调至 “卖出”。</p>
</div><p>Get <strong>Lucid Diagnostics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Lucid Diagnostics</strong> 的提醒：</p>
</div><ul>
<li>October's 4 Best Penny Stocks: High-Risk, High-Reward Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>十月四只最佳便士股票：高风险，高回报的选择</li>
</ul>
</div><p>LUCD has been the subject of several other reports. Ascendiant Capital Markets lifted their price objective on Lucid Diagnostics from $8.25 to $9.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, April 9th. Needham &amp; Company LLC reiterated a &#34;buy&#34; rating and issued a $3.00 price target on shares of Lucid Diagnostics in a report on Thursday, March 26th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Lucid Diagnostics in a report on Wednesday. Finally, BTIG Research reiterated a &#34;buy&#34; rating and issued a $2.50 price target on shares of Lucid Diagnostics in a report on Monday, March 30th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $4.13.</p>
<div class="lb-trans"><p>LUCD 曾受到其他几份报告的关注。Ascendiant Capital Markets 将 Lucid Diagnostics 的目标价格从 8.25 美元上调至 9.00 美元，并在 4 月 9 日的研究报告中给予该股票 “买入” 评级。Needham &amp; Company LLC 在 3 月 26 日的报告中重申了 “买入” 评级，并对 Lucid Diagnostics 的股票设定了 3.00 美元的目标价。Weiss Ratings 在周三的报告中重申了 Lucid Diagnostics 的 “卖出（d-）” 评级。最后，BTIG Research 在 3 月 30 日的报告中重申了 “买入” 评级，并对 Lucid Diagnostics 的股票设定了 2.50 美元的目标价。四位股票研究分析师给予该股票 “买入” 评级，一位分析师给予该股票 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 4.13 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Lucid Diagnostics</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Lucid Diagnostics 的最新股票报告</strong></p>
</div><h2>Lucid Diagnostics Price Performance</h2>
<div class="lb-trans"><h2>Lucid Diagnostics 价格表现</h2>
</div><p>Shares of Lucid Diagnostics stock opened at $1.03 on Friday. Lucid Diagnostics has a 1 year low of $0.95 and a 1 year high of $1.70. The company has a market capitalization of $201.11 million, a P/E ratio of -1.07 and a beta of 1.10. The business has a 50 day moving average price of $1.25 and a 200 day moving average price of $1.19.</p>
<div class="lb-trans"><p>Lucid Diagnostics 的股票在周五开盘价为 1.03 美元。Lucid Diagnostics 的 1 年最低价为 0.95 美元，1 年最高价为 1.70 美元。该公司的市值为 2.0111 亿美元，市盈率为-1.07，贝塔值为 1.10。该业务的 50 日移动平均价格为 1.25 美元，200 日移动平均价格为 1.19 美元。</p>
</div><p>Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) last issued its quarterly earnings data on Wednesday, March 25th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The company had revenue of $1.50 million during the quarter, compared to analysts' expectations of $1.39 million. As a group, research analysts expect that Lucid Diagnostics will post -0.22 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Lucid Diagnostics（纳斯达克股票代码：LUCD - 获取免费报告）最近在 3 月 25 日发布了季度财报。该公司报告每股收益（EPS）为（0.10）美元，低于共识预期的（0.07）美元，差额为（0.03）美元。该公司在本季度的收入为 150 万美元，而分析师预期为 139 万美元。整体而言，研究分析师预计 Lucid Diagnostics 在当前财政年度将发布-0.22 的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors have recently bought and sold shares of the business. Centiva Capital LP acquired a new position in Lucid Diagnostics in the 3rd quarter valued at $25,000. Sprott Inc. acquired a new stake in shares of Lucid Diagnostics during the 3rd quarter worth $25,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Lucid Diagnostics during the 1st quarter worth $39,000. SG Americas Securities LLC acquired a new stake in shares of Lucid Diagnostics during the 3rd quarter worth $26,000. Finally, Abel Hall LLC acquired a new stake in shares of Lucid Diagnostics during the 4th quarter worth $33,000. 74.01% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者最近买入和卖出了该公司的股票。Centiva Capital LP 在第三季度以 25,000 美元的估值收购了 Lucid Diagnostics 的新头寸。Sprott Inc.在第三季度收购了 Lucid Diagnostics 的股份，价值 25,000 美元。Cubist Systematic Strategies LLC 在第一季度以 39,000 美元的价值收购了 Lucid Diagnostics 的新股份。SG Americas Securities LLC 在第三季度以 26,000 美元的价值收购了 Lucid Diagnostics 的新股份。最后，Abel Hall LLC 在第四季度以 33,000 美元的价值收购了 Lucid Diagnostics 的新股份。目前 74.01% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Lucid Diagnostics Company Profile</h2>
<div class="lb-trans"><h2>Lucid Diagnostics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company's flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid's CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.</p>
<div class="lb-trans"><p>Lucid Diagnostics 是一家分子诊断公司，专注于改善口腔和咽喉癌的早期检测。该公司的旗舰产品 LucidDx 口腔细胞学刷检测试剂，结合了一种微创的刷子活检工具和专有的实验室分析，以识别指示恶性肿瘤的细胞异常。在牙科和医疗办公室收集的样本被送往 Lucid 的 CLIA 认证和 CAP 认可的实验室，在那里，先进的成像和细胞病理工作流程生成诊断报告供临床医生和患者使用。</p>
</div><p>Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.</p>
<div class="lb-trans"><p>自开始商业运营以来，Lucid Diagnostics 一直致力于将其检测平台整合到美国的牙科诊所、口腔外科诊所和耳鼻喉科专家中。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Lucid Diagnostics</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Lucid Diagnostics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFVDRA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=LUCD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Lucid Diagnostics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Lucid Diagnostics 吗？</h2>
</div><p>Before you consider Lucid Diagnostics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Lucid Diagnostics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lucid Diagnostics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Lucid Diagnostics 并不在名单上。</p>
</div><p>While Lucid Diagnostics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Lucid Diagnostics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Lucid Diagnostics（纳斯达克股票代码：LUCD）的股票评级被 Wall Street Zen 下调